Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRPT
CUSIPN/A
Phone617-274-4000
Debt
Debt-to-Equity Ratio0.55
Current Ratio13.37
Quick Ratio12.28
Price-To-Earnings
Trailing P/E Ratio-80.21
Forward P/E Ratio-67.39
P/E GrowthN/A
Sales & Book Value
Annual Sales$154.58 million
Price / Sales56.28
Cash FlowN/A
Price / CashN/A
Book Value$12.21 per share
Price / Book10.87
Profitability
EPS (Most Recent Fiscal Year)($1.64)
Net Income$-50,680,000.00
Net Margins-83.88%
Return on Equity-24.68%
Return on Assets-16.89%
Miscellaneous
Employees255
Outstanding Shares65,530,000
Market Cap$8,735.94
Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions
What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
How were Sarepta Therapeutics' earnings last quarter?
Sarepta Therapeutics Inc (NASDAQ:SRPT) released its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.23. The biotechnology company had revenue of $64.60 million for the quarter, compared to analysts' expectations of $65.31 million. Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The firm's quarterly revenue was up 295.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.57) EPS. View Sarepta Therapeutics' Earnings History.
When is Sarepta Therapeutics' next earnings date?
What price target have analysts set for SRPT?
22 Wall Street analysts have issued 1-year price objectives for Sarepta Therapeutics' stock. Their predictions range from $56.51 to $275.00. On average, they expect Sarepta Therapeutics' stock price to reach $152.6755 in the next twelve months. This suggests a possible upside of 15.0% from the stock's current price. View Analyst Ratings for Sarepta Therapeutics.
What is the consensus analysts' recommendation for Sarepta Therapeutics?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 19 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Sarepta Therapeutics' key competitors?
Some companies that are related to Sarepta Therapeutics include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF) and Perrigo (PRGO).
Who are Sarepta Therapeutics' key executives?
Sarepta Therapeutics' management team includes the folowing people:
- Mr. Douglas S. Ingram, Pres, CEO & Director (Age 55)
- Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 53)
- Dr. Guriqbal S. Basi Ph.D., Sr. VP & Chief Scientific Officer (Age 61)
- Mr. David Tyronne Howton Jr., Sr. VP, Gen. Counsel & Corp. Sec. (Age 46)
- Mr. Alexander Bo Cumbo, Sr. VP & Chief Commercial Officer (Age 47)
Has Sarepta Therapeutics been receiving favorable news coverage?
Headlines about SRPT stock have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sarepta Therapeutics earned a coverage optimism score of 0.14 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Sarepta Therapeutics' major shareholders?
Sarepta Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fred Alger Management Inc. (2.38%), Bank of Montreal Can (0.16%), Creative Planning (0.11%), Fisher Asset Management LLC (0.05%), Handelsbanken Fonder AB (0.05%) and Sit Investment Associates Inc. (0.03%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Jayant Aphale, Richard Barry, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.
Which institutional investors are selling Sarepta Therapeutics stock?
SRPT stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Boston Advisors LLC, Creative Planning, Sit Investment Associates Inc., Fisher Asset Management LLC, Handelsbanken Fonder AB, Campbell & CO Investment Adviser LLC and Empowered Funds LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, David T Howton, Hans Lennart Rudolf Wigzell, Richard Barry and Shamim Ruff. View Insider Buying and Selling for Sarepta Therapeutics.
Which institutional investors are buying Sarepta Therapeutics stock?
SRPT stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, State of Alaska Department of Revenue, Amalgamated Bank, Harbour Capital Advisors LLC, ETF Portfolio Partners Inc., World Asset Management Inc, XR Securities LLC and Clarus Wealth Advisors. View Insider Buying and Selling for Sarepta Therapeutics.
How do I buy shares of Sarepta Therapeutics?
Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sarepta Therapeutics' stock price today?
One share of SRPT stock can currently be purchased for approximately $132.75.
How big of a company is Sarepta Therapeutics?
Sarepta Therapeutics has a market capitalization of $8.74 billion and generates $154.58 million in revenue each year. The biotechnology company earns $-50,680,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Sarepta Therapeutics employs 255 workers across the globe.
How can I contact Sarepta Therapeutics?
Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]
MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ SRPT)
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
